Baodong Liu

Chinese expert consensus workshop report: Guidelines for thermal ablation of primary and metastatic lung tumors

Although surgical resection is the primary means of curing both primary and metastatic lung cancers, about 80% of lung cancers cannot be removed by surgery. As most patients with unresectable lung cancer receive only limited benefits from traditional radiotherapy and chemotherapy, many new local treatment methods have emerged, including local ablation therapy. The Minimally Invasive and Comprehensive Treatment of Lung Cancer Branch, Professional Committee of Minimally Invasive Treatment of Cancer of the Chinese Anti‐Cancer Association has organized multidisciplinary experts to develop guidelines for this treatment modality. These guidelines aim at standardizing thermal ablation procedures and criteria for selecting treatment candidates and assessing outcomes; and for preventing and managing post‐ablation complications.

Percutaneous radiofrequency ablation for medically inoperable patients with clinical stage I non‐small cell lung cancer

A retrospective evaluation of percutaneous radiofrequency ablation (RFA) in medically inoperable patients with clinical stage I non‐small cell lung cancer (NSCLC).

Effect of percutaneous radiofrequency ablation after thoracoscopic pleurodesis for treating non-small cell lung cancer patients with malignant pleural effusion and/or pleural dissemination

The purpose of this study was to retrospectively evaluate percutaneous radiofrequency ablation (RFA) combined with palliative thoracoscopic pleurodesis (TP) for malignant pleural effusion and/or pleural disseminated non‐small cell lung cancer (NSCLC), diagnosed by thoracoscopy.

Evaluation of Three-Dimensional Reconstruction CT in Percutaneous Radiofrequency Ablation (RFA) of the Unresectable Lung Tumor with a Clustered Electrode

BACKGROUND Radiofrequency ablation (RFA) of lung tumours has recently received much attention for the promising results achieved. Here, to evaluate the value of three-dimensional reconstruction CT in radiofrequency ablation (RFA) of advanced non-small cell lung cancer. METHODS Sixty-six cases of advanced non-small cell lung cancer with 68 lesions (2 patients had 2 lesion treated in one session) were underwent three-dimensional reconstruction CT-giuded percutaneous RFA therapy. To evaluate short-term therapeutic effect of lung tumors using spiral CT scanning in 1-3 months after RFA to investigate the alterations of tumor size and density pre-and post-procedure, and complications, to observe the short-term curative effect. RESULTS Our experiences have shown an initial increase in lesion size at immediate follow-up CT. The density of 64 lesions was lowered (94.1%) and 4 lesion is increased (5.9%) at immediate and one month follow-up CT. SPECT scan findings that 82.4% (56/68) cases of FDG uptake in tumors after RFA with tumor/non-tumor of lower than 2.5 at one month follow-up. The change in treated lesion size over time, radiologically assessed through measurements of the lesions on axial CT scans in the lung window setting no lesions had complete response, 50 lesions (73.5%) had partial response, 2 lesions with stable disease, 6 lesions showed progressive disease at 3 month follow-up CT. SPECT scan findings that 79.4% (54/68) cases of FDG uptake in tumors after RFA with tumor/non-tumor of lower than 2.5 at 3 month follow-up. CONCLUSIONS The percutaneous RFA therapy under the guidance of three-dimensional reconstruction CT scan is safe and effective, with few complications, and can serve as a new method to the treatment of advanced non-small cell lung cancers.

Giant solitary fibrous tumor of the pleura: A case report

A 62‐year‐old male farmer weighing 79 kg was taken to a hospital after experiencing exertional dyspnea and shortness of breath for a month. A chest roentgenogram and computed tomography showed a giant mass in his right thorax. A CT‐guided biopsy demonstrated a solitary fibrous tumor of the pleura (SFTP). Because of the large size of the tumor and the substantial pleural effusion in the right hemithorax, the patient was referred to our institution for radiofrequency ablation. After one month, we performed an exploratory thoracotomy to dissect the giant mass with the right, middle, and lower lobes. The measurement of the tumor was 20 cm × 18 cm × 13 cm and it weighed 3250 g. The histopathology of the resected specimen confirmed SFTP. The patient had no postoperative complications; six months after surgery, no recurrence occurred.

Expert consensus on image-guided radiofrequency ablation of pulmonary tumors: 2018 edition: Expert consensus on RFA

Lung cancer ranks first in incidence and mortality in China. Surgery is the primary method to cure cancer, but only 20–30% of patients are eligible for curative resection. In recent years, in addition to surgery, other local therapies have been developed for patients with numerous localized primary and metastatic pulmonary tumors, including stereotactic body radiation therapy and thermal ablative therapies through percutaneously inserted applicators. Percutaneous thermal ablation of pulmonary tumors is minimally invasive, conformal, repeatable, feasible, cheap, has a shorter recovery time, and offers reduced morbidity and mortality. Radiofrequency ablation (RFA), the most commonly used thermal ablation technique, has a reported 80–90% rate of complete ablation, with the best results obtained in tumors < 3 cm in diameter. Because the clinical efficacy of RFA of pulmonary tumors has not yet been determined, this clinical guideline describes the techniques used in the treatment of localized primary and metastatic pulmonary tumors in nonsurgical candidates, including mechanism of action, devices, indications, techniques, potential complications, clinical outcomes, post‐ablation surveillance, and use in combination with other therapies. In the future, the role of RFA in the treatment of localized pulmonary tumors should ultimately be determined by evidence from prospective randomized controlled trials comparing sublobar resection or stereotactic body radiation therapy.

Associations between epidermal growth factor receptor mutations and histological subtypes of lung adenocarcinoma according to the IASLC/ATS/ERS classification in Chinese patients.

This retrospective study was conducted to investigate the relationship between epidermal growth factor receptor (EGFR) mutation and histological subtypes of lung adenocarcinoma according to the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society (IASLC/ATS/ERS) classification in Chinese patients.

Expert consensus for thermal ablation of primary and metastatic lung tumors (2017 edition)

Expert Consensus for Thermal Ablation of Primary and Metastatic Lung Tumors (2017 Edition) Xin YE, Weijun FAN, Hui WANG, Junjie WANG, Shanzhi GU, Weijian FENG, Yiping ZHUANG, Baodong LIU, Xiaoguang LI, Yuliang LI, Po YANG, Xia YANG, Wuwei YANG, Junhui CHEN, Rong ZHANG, Zhengyu LIN, Zhiqiang MENG, Kaiwen HU, Chen LIU, Zhongmin PENG, Yue HAN, Yong JIN, Guangyan LEI, Bo ZHAI, Guanghui HUANG, Minimally Invasive Treatment of Lung Cancer Branch, Professional Commitee of Minimally Invasive Treatment of Cancer, Chinese Anti-Cancer Association Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Ji’nan 250014, China; Imaging and Interventional Center, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; Interventional Treatment Center, Jilin Provincial Tumor Hospital, Changchun 130012, China; Department of Radiation Oncology, Peking University 3 Hospital, Beijing 100191, China; Department of Interventional Therapy, Hunan Provincial Tumor Hospital, Changsha 410013, China; Department of Oncology, Fuxing Hospital Affiliated to the Capital University of Medical Sciences, Beijing 100045, China; Department of Interventional Therapy, Jiangsu Cancer Hospital, Nanjing 210009, China; Department of Thoracic Surgery, Xuanwu Hospital Affiliated to the Capital University of Medical Sciences, Beijing 100053, China; Department of Tumor Minimally Invasive Therapy, Beijing Hospital, Beijing 100005, China; Interventional Treatment Center, Shandong University Second Hospital, Ji’nan 250033, China; Department of Interventional Radiology, The Fourth Hospital of Harbin Medical University, Harbin 150001, China; Department of Tumor Minimally Invasive Therapy, 307 Hospital, Beijing 100071, China; Department of Minimally Invasive Interventional Therapy, Shenzhen Hospital of Beijing University, Shenzhen 518036, China; Department of Interventional Therapy, the First Affiliated Hospital of Fujian Medical University, Fuzhou 350005, China; Department of Integrative Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Dongfang Hospital Affiliated to Beijing University of Chinese Medicine, Beijing 100078, China; Department of Interventional Therapy, Beijing Cancer Hospital, Beijing 100083, China; Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Ji’nan 250014, China; Department of Interventional Therapy, Tumor Institute and Hospital, Chinese Academy of Medical Sciences, Beijing 100021, China; Department of Interventional Therapy, the Second Affiliated Hospital of Soochow University, Suzhou 215004, China; Department of Thoracic Surgery, Shanxi Provincial Tumor Hospital, Xi’an 710061, China; Tumor Interventional Therapy Center, Shanghai Renji Hospital, Shanghai 200127, China Corresponding author: Weijun FAN, E-mail: Fanweijun1964@126.com Xin YE, E-mail: yexintaian@aliyun.com DOI: 10.3779/j.issn.1009-3419.2017.07.01